FDA 批准礼来公司的 Kisunla（donanemab）用于治疗早期阿尔茨海默病患者，目标是治疗淀粉样斑块。 The FDA approved Eli Lilly's Kisunla (donanemab) for early Alzheimer's patients, targeting amyloid plaques.

美国食品药品监督管理局（FDA）批准了一种治疗阿尔茨海默病的新药，即礼来公司的 Kisunla（donanemab），用于治疗早期症状性阿尔茨海默病的成年人。 The U.S. Food and Drug Administration (FDA) has approved a new medication for Alzheimer's disease, Eli Lilly's Kisunla (donanemab), for adults with early-symptomatic Alzheimer's disease. 这是第一种针对淀粉样斑块（阿尔茨海默病患者脑内堆积的蛋白质）的药物，有证据表明当淀粉样斑块被清除时就应该停止治疗。 It is the first drug to target amyloid plaques, proteins that build up in the brains of Alzheimer's patients, with evidence to support stopping therapy when amyloid plaques are removed.